Esoteric Testing Market By Type (Infectious Disease Testing, Oncology Testing, Endocrinology Testing, Genetic Testing, Toxicology Testing, Immunology Testing, Neurology Testing, Other Testings), By Technology (Enzyme-linked Immunosorbent Assay, Chemiluminescence Immunoassay, Mass Spectrometry, Real Time Polymerase Chain Reaction, DNA Sequencing, Flow Cytometry, Other Technologies), By End User (Hospital-based Laboratories, Independent and Reference Laboratories): Global Opportunity Analysis and Industry Forecast, 2023-2032
The esoteric testing market was valued at $24.2 billion in 2022 and is estimated to reach $68.5 billion by 2032, exhibiting a CAGR of 11.0% from 2023 to 2032. Esoteric testing is defined as the analysis of rare molecules that are not performed in routine clinical labs. This analysis is done by using various technologies such as real time polymerase chain reaction, enzyme linked immunosorbent assay, flow cytometry, and DNA sequencing. These tests require specialized equipment and are performed on a small scale. It requires skilled personnel to conduct these tests and analyze the result by using various chemical agents and sophisticated instruments. Esoteric testing is generally performed for the diagnosis of rare diseases, infectious diseases, and endocrine diseases.
The esoteric testing market growth is significantly driven by increase in the prevalence of chronic diseases such as cancer, hypertension, diabetes and chronic infectious diseases; surge in awareness about importance of early disease diagnosis; and increase in new test launches. Esoteric tests are designed to detect specific markers to enable more precise diagnosis and prognosis of chronic diseases such as cancer and HIV. For instance, according to American Cancer Society (ACS), about 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2022. Thus, rise in prevalence of chronic diseases drives the demand for specialized, esoteric tests.
Furthermore, surge in awareness about early disease diagnosis among the general population has increased the demand for esoteric testing. Awareness campaigns, educational seminars, and training programs emphasize the importance of early disease diagnosis. For instance, F. Hoffmann-La Roche Ltd., supports local community partners to run screening programs and counselling programs for diseases such as cancers, hepatitis, tuberculosis, HIV, HPV, cardiovascular disease and diabetes. Moreover, technological advancements and new product launches further drive the market growth. For instance, Laboratory Corporation of America Holdings, a global life sciences company, launched its new Neurofilament Light Chain (NfL) blood test that provides direct evidence of neurodegeneration and neuronal injury. This test will allow doctors to identify and verify signs of neurodegenerative diseases.
However, the high cost associated with esoteric testing and lack of skilled laboratory technicians are anticipated to hinder the market growth during the forecast period. On the other hand, increase in the number of diagnostic testing and technological advancements in DNA sequencing are expected to create lucrative opportunities for market growth during the forecast period.
The esoteric testing market is segmented into type, technology, end user, and region. By type, the market is categorized into infectious disease testing, oncology testing, endocrinology testing, genetic testing, toxicology testing, immunology testing, neurology testing, and other testing. By technology, the market is divided into enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass-spectrometry, real time polymerase chain reaction, DNA sequencing, flow cytometry, and other technologies. By end user, the market is bifurcated into hospital-based laboratories and independent & reference laboratories. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global esoteric testing market are Laboratory Corporation of America Holdings, ARUP Laboratories, Opko Health, Inc., Quest Diagnostics Inc., F. Hoffmann-La Roche Ltd., Mayo Foundation for Medical Education and Research, Stanford Health Care, Healius Limited, Athena Esoterix, LLC, and Sonic Healthcare Limited. Key players operating in the market have adopted product launch, collaboration, and product approval as key strategies to expand their market share and product portfolio.
Key Benefits for StakeholdersThis report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the esoteric testing market analysis from 2022 to 2032 to identify the prevailing esoteric testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the esoteric testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global esoteric testing market trends, key players, market segments, application areas, and market growth strategies.
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis
Key Market SegmentsBy TypeInfectious Disease Testing
Oncology Testing
Endocrinology Testing
Genetic Testing
Toxicology Testing
Immunology Testing
Neurology Testing
Other Testings
By TechnologyEnzyme-linked Immunosorbent Assay
Chemiluminescence Immunoassay
Mass Spectrometry
Real Time Polymerase Chain Reaction
DNA Sequencing
Flow Cytometry
Other Technologies
By End UserHospital-based Laboratories
Independent and Reference Laboratories
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market PlayersARUP Laboratories
Quest Diagnostics Inc.
F. Hoffmann-La Roche Ltd.
Stanford Health Care
Healius Limited
Laboratory Corporation of America Holdings
Opko Health, Inc.
Mayo Foundation for Medical Education and Research
Athena Esoterix, LLC.
Sonic Healthcare Limited
Please Note: It will take 7-10 business days to complete the report upon order confirmation.